Cited by 356Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchAntiplatelet Therapy and Cardiovascular Diseases

The DOI matches its Crossref record, with a small difference in title or year; 9 of the 9 references it cites were found in a registry or an index.

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Open access

Ray, Kausik K., Cannon, Christopher P., McCabe, Carolyn H., Cairns, Richard, Tonkin, Andrew M., Sacks, Frank M., Jackson, Graham, Braunwald, Eugene·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2005.03.077

Open this paper in CoChat — free account Open PDF

Abstract

Objectives Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients.Background The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin therapy improved clinical outcomes over two years in ACS patients versus standard therapy. The relative contributions of early or late effects to the overall clinical efficacy of intensive therapy are presently unclear.Methods A total of 4,162 patients with ACS were recruited in the PROVE IT-TIMI 22 trial. Patients were randomized to intensive statin therapy (atorvastatin, 80 mg) or standard therapy (pravastatin, 40 mg). The composite triple end point of death, MI, or rehospitalization for recurrent ACS was determined in each group at 30 days. The composite triple and primary end points were assessed in stable patients from six months to the end of study, after censoring for clinical events before six months.Results The composite end point at 30 days occurred in 3.0% of patients receiving atorvastatin 80 mg versus 4.2% of patients receiving pravastatin 40 mg (hazard ratio [HR] = 0.72; 95% confidence interval [CI], 0.52 to 0.99; p = 0.046). In stable patients, atorvastatin 80 mg was associated with a composite event rate of 9.6% versus 13.1% in the pravastatin 40 mg group (HR = 0.72; 95% CI, 0.58 to 0.89; p = 0.003).Conclusions Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects. In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2005.03.077

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citation
Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban
Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R. M., Frey, M. J., Lakkis, N. M., Neumann, F., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,093
Self-citation
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto‐Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M. J., & Koskela, P. U. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,691
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation
Ray, K., & Cannon, C. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-004-0205-9 · Cited by 43
Self-citation

Show all 9 references

Research works printed but not linked: 1

1994, Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, Lancet, 344, 1383

Sorted by citations

Items 101–200 of 356

Variations in time to benefit among clinical trials of cholesterol-lowering drugs
Barter, P. J., & Waters, D. D. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.006 · Cited by 33
[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Spanish adaptation of the CEIPC 2008].
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · PubMed · Cited by 32
Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes
Colivicchi, F., Marco Tubaro, U., & Santini, M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.07.006 · Cited by 30
Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study
Galve, E., Cordero, A., Cequier, A. R., Ruiz, E., & González‐Juanatey, J. R. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.02.012 · Cited by 30
HMG-CoA Reductase Inhibitor Improves Endothelial Dysfunction in Spontaneous Hypertensive Rats Via Down-regulation of Caveolin-1 and Activation of Endothelial Nitric Oxide Synthase
Suh, J., Choi, D., Chang, H., Cho, Y., Youn, T., Chae, I., Kim, K., Kim, C.-H., Kim, H.-S., Oh, B., et al. (2009) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.1.16 · Cited by 30
Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol
Corsini, A., Windier, E. T. E., & Farnier, M. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32831215db · Cited by 30
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin
Bybee, K. A., Lee, J., & O’Keefe, J. H. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x292001 · Cited by 29
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs
Gupta, A., Guyomard, V., Zaman, M., Rehman, H. U., & Myint, P. K. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0033-6 · Cited by 28
Inhibition of Platelet-Rich Arterial Thrombus In Vivo
Obi, C., Wysokiński, W. E., Karnicki, K., Owen, W. G., & McBane, R. D. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.190884 · Cited by 28
Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency
Phrommintikul, A., Chinwong, D., Patumanond, J., Chinwong, S., Siriwattana, K., Gunaparn, S., & Hall, J. J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s75608 · Cited by 27
The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy
Wiviott, S. D., & Cannon, C. P. (2006) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328010872d · Cited by 27
Self-citation
Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing
Choi, S.-W., Choi, D.-H., Kim, H., Ku, Y.-H., Ha, S.-I., & Park, G. (2013) · Platelets · doi:10.3109/09537104.2013.821606 · Cited by 26
Early Statin Therapy in Acute Coronary Syndromes
Waters, D. D., & Ku, I. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.062 · Cited by 27
Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial
Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23112 · Cited by 26
Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets
Brie, D. M., Mornoş, C., Adam, O., Tîrziu, A., Popescu, R., & Brie, A. D. (2025) · Cells · doi:10.3390/cells15010072 · Cited by 33
Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke
Fletcher, G. F., Bufalino, V. J., Costa, F., Goldstein, L. B., Jones, D., Smaha, L. A., Smith, S. C., & Stone, N. J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.001 · Cited by 27
Lipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 26
Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome
Rodés‐Cabau, J., Tardif, J., Cossette, M., Bertrand, O. F., Ibrahim, R., Larose, É., Grégoire, J. C., L’Allier, P. L., & Guertin, M. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.009 · Cited by 25
Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report
Mrotzek, S. M., Rassaf, T., & Totzeck, M. (2017) · American Journal of Case Reports · doi:10.12659/ajcr.905974 · Cited by 25
Pregnancy-Associated Plasma Protein-A Elevation in Patients With Acute Coronary Syndrome and Subsequent Atorvastatin Therapy
Miedema, M. D., Conover, C. A., MacDonald, H., Harrington, S. C., Oberg, D., Wilson, D. J., Henry, T. D., & Schwartz, R. S. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.07.045 · Cited by 25
“Vascular inflammation and cardiovascular disease: review about the role of PET imaging”
Sammartino, A. M., Falco, R., Drera, A., Dondi, F., Bellini, P., Bertagna, F., & Vizzardi, E. (2022) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-022-02730-9 · Cited by 25
Clopidogrel-statin interaction: A mountain or a mole hill?
Steinhubl, S. R., & Akers, W. S. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.01.001 · Cited by 24
Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction
Patti, G., Cumitini, L., Bosco, M., Marengo, A., D’Amario, D., Mennuni, M. G., Solli, M., & Grisafi, L. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf004 · Cited by 23
High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study
Pauriah, M., Elder, D. H. J., Ogston, S. A., Noman, A., Majeed, A., Wyatt, J. C., Choy, A. M., MacDonald, T. M., Struthers, A. D., & Lang, C. C. (2014) · Heart · doi:10.1136/heartjnl-2013-304678 · Cited by 25
Statins in acute coronary syndrome: very early initiation and benefits
Angeli, F., Reboldi, G., Mazzotta, G., Garofoli, M., Cerasa, M. F., & Verdecchia, P. (2012) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944712452463 · Cited by 23
Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry)
Lowenstern, A. M., Návar, A. M., Li, S., Virani, S. S., Goldberg, A. C., Louie, M. J., Lee, L. V., Peterson, E. D., & Wang, T. Y. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.12.031 · Cited by 23
Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India
Puri, R., Mehta, V., Duell, P. B., Iyengar, S. S., Yusuf, J., Dalal, J., Narasingan, S. N., Kalra, D. K., Kapoor, A., Pradhan, A. K., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.008 · Cited by 22
Return to work after coronary artery bypass surgery. A 10-year follow-up study
Hällberg, V., Palomäki, A., Kataja, M., & Tarkka, M. R. (2008) · Scandinavian Cardiovascular Journal · doi:10.1080/14017430802506601 · Cited by 22
Plaque-Stabilizing Effect of Atorvastatin Is Stronger for Plaques Evaluated as More Unstable by Angioscopy and Intravenous Ultrasound
Hirayama, A., Saito, S., Ueda, Y., Takayama, T., Honye, J., Komatsu, S., Yamaguchi, O., Li, Y., Yajima, J., Nanto, S., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1035 · Cited by 22
Lower serum triglyceride level is a risk factor for in-hospital and late major adverse events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention- a cohort study
Cheng, Y., Liu, T.-J., Lai, H., Lee, W.-L., Ho, H., Su, C., Liu, C.-N., & Wang, K. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-143 · Cited by 23
Controversial Treatment of Atherosclerotic Renal Vascular Disease
Dworkin, L. D. (2006) · Hypertension · doi:10.1161/01.hyp.0000233513.19720.b7 · Cited by 22
Effects of atorvastatin on serum lipids, serum inflammation and plaque morphology in patients with stable atherosclerotic plaques
Guo, S., Wang, R., Yang, Z., Li, K.-L., & Wang, Q. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.722 · Cited by 22
Current status of lipid management in acute coronary syndrome
Fujisue, K., & Tsujita, K. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.02.004 · Cited by 22
Measurement of Low‐Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry
Lowenstern, A. M., Li, S., Návar, A. M., Roger, V. L., Robinson, J. G., Goldberg, A. C., Virani, S. S., Lee, L. V., Wilson, P. W. F., Louie, M. J., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009251 · Cited by 21
2022 Saudi Guidelines for the Management of Dyslipidemia
Alrahimi, J. S., AlSaif, S. M., Alasnag, M. A., Awan, Z. A., Almutairi, F., Mudaiheem, H. Y. A., Gencer, B., Catapano, A. L., Mach, F., & Tash, A. A. (2023) · Heart Views · doi:10.4103/heartviews.heartviews_102_22 · Cited by 21
Role of statins in the management of dyslipidaemia
Ray, S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.267 · Cited by 20
Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease
Nakamura, M., Yamashita, T., Yajima, J., Oikawa, Y., Ogasawara, K., Sagara, K., Koike, A., Kirigaya, H., Nagashima, K., Otsuka, T., et al. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2010.11.004 · Cited by 20
A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women
Hamrefors, V., Orho‐Melander, M., Krauss, R. M., Hedblad, B., Almgren, P., Berglund, G. L., & Melander, O. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p001792 · Cited by 21
Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study
Kristensen, M. S., Green, A., Nybo, M., Hede, S. M., Mikkelsen, K. H., Gislason, G., Larsen, M. L., & Ersbøll, A. K. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01616-9 · Cited by 20
[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish adaptation].
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · PubMed · Cited by 20
Current management and prognosis of patients with recurrent myocardial infarction
Luca, L. D., Paolucci, L., Nusca, A., Putini, R. L., Mangiacapra, F., Natale, E., Ussia, G. P., Colivicchi, F., Grigioni, F., Musumeci, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203080 · Cited by 20
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction
Schwartz, G. G., & Giugliano, R. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000830 · Cited by 19
Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida
y otras, C. G. D. T. C. D. L. S. E. D. C., & Clínica, S. S. P. D. L. E. C. E. L. P. (2008) · Revista Española de Cardiología · doi:10.1157/13114961 · Cited by 19
Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry
Lowenstern, A. M., Li, S., Návar, A. M., Virani, S. S., Lee, L. V., Louie, M. J., Peterson, E. D., & Wang, T. Y. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.011 · Cited by 19
Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm
FITCHETT, D. H., Borgundvaag, B., Cantor, W. J., Cohen, E. A., Dhingra, S., Fremes, S. E., Gupta, M., Heffernan, M., Kertland, H. R., Husain, M., et al. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70935-7 · Cited by 19
Current questions regarding the use of statins in patients with coronary heart disease
Rallidis, L. S., Lekakis, J. P., & Kremastinos, D. T. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.12.030 · Cited by 19
Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care
Ray, K. K. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1008 · Cited by 19
Self-citation
Rosuvastatin Alleviates Ischemia/Reperfusion Injury in Cardiomyocytes by Downregulating Hsa-miR-24-3p to Target Upregulated Uncoupling Protein 2
Wei, W., Peng, J., & Shen, T. (2019) · Cellular Reprogramming · doi:10.1089/cell.2018.0039 · Cited by 18
JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
Shishehbor, M. H., & Hazen, S. L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75a.08105 · Cited by 19
The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience
D, E. B. M., & Sabatine, M. S. (2012) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2012.07.001 · Cited by 18
Long-term Effect of Chronic Oral Anticoagulation with Warfarin after Acute Myocardial Infarction
Haq, S., Heitner, J. F., Sacchi, T. J., & Brener, S. J. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.08.016 · Cited by 18
Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies
Tonelli, M. A., Wiebe, N., Nadler, B., Darzi, A. W., & Rasheed, S. (2016) · BMJ Global Health · doi:10.1136/bmjgh-2016-000128 · Cited by 18
Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits
Xiaoqiao, W., Yongqin, L., Nian-sang, L., Zhongqing, C., Gu, M.-N., Jingfeng, W., & Yangxin, C. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20133011 · Cited by 17
Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention
Yun, K. H., Shin, I.-S., Shin, S.-N., Choi, J. H., Kim, S. H., Rhee, S. J., Lee, E. M., Yoo, N. J., Kim, N., Oh, S. K., et al. (2011) · Korean Circulation Journal · doi:10.4070/kcj.2011.41.8.458 · Cited by 17
Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia
Meuwese, M. C., Trip, M. D., van Wissen, S., van Miert, J. N. I., Kastelein, J. J. P., & Stroes, E. S. G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.011 · Cited by 17
Evidence‐Based Optimal Medical Therapy and Mortality in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention
Lee, K., Han, S., Lee, M., Kim, D., Kwon, J.-B., Park, G., & Park, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.121.024370 · Cited by 17
Importance of Intensive Lipid Lowering in Acute Coronary Syndrome and Percutaneous Coronary Intervention
Kumar, A., & Cannon, C. P. (2007) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2007.00298.x · Cited by 16
Self-citation
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Sala, L. A., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano, A. P. R., et al. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)71477-8 · Cited by 16
The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident.
Sadeghi, R., Piranfar, M. A., Asadollahi, M., Taherkhani, M., & Baseri, F. (2014) · Europe PMC (PubMed Central) · Cited by 16
Pleiotropic vasoprotective effects of statins: The chicken or the egg?
Kirmizis, D. A., & Chatzidimitriou (2009) · Drug Design Development and Therapy · doi:10.2147/dddt.s5407 · Cited by 17
Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing
Meredith, K. G., Horne, B. D., Pearson, R. R., Maycock, C. A. A., LAPPE, D. L., Anderson, J. L., & Muhlestein, J. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.07.079 · Cited by 16
Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention
Athyros, V. G., Katsiki, N., Karagiannis, A. I., & Mikhailidis, D. P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.954666 · Cited by 15
A review of statin use in patients with acute coronary syndrome in Western and Japanese populations
Miyauchi, K., & Ray, K. K. (2013) · Journal of International Medical Research · doi:10.1177/0300060513476428 · Cited by 15
Self-citation
The Application of the LDL Principle
Schade, D. S., Cavanaugh, B., Ramo, B. W., & Eaton, R. P. (2016) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2016.65012 · Cited by 15
The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes
Argan, O., Çıkrıkçı, K., Baltacı, A., & Gençer, N. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1781844 · Cited by 15
Recent trials of lipid lowering
Ray, K. K., Cannon, C. P., & Braunwald, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01425.x · Cited by 16
Self-citation
Plaque characteristics and inflammatory markers for the prediction of major cardiovascular events in patients with ST-segment elevation myocardial infarction
Her, A., Cho, K. I., Singh, G. B., An, D. S., Jeong, Y., Koo, B., & Shin, E. (2017) · International journal of cardiac imaging · doi:10.1007/s10554-017-1135-x · Cited by 14
Unstable Angina and Non–ST Elevation Myocardial Infarction
Cannon, C. P., & Braunwald, E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00056-1 · Cited by 16
Self-citation
Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007)
Gohlke, H., Albus, C., Gysan, D. B., Hahmann, H., & Mathes, P. (2009) · Herz · doi:10.1007/s00059-009-3196-7 · Cited by 14
Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention
Forzano, I., Florimonte, D., Narciso, V., Canonico, M. E., Castiello, D. S., Manzi, L., Cristiano, S., Spinelli, A. M., Vallone, D. M., D’Alconzo, D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238334 · Cited by 17
Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome
Vázquez, R., García, J. E. P., Navas, W. D., Salmerón, D. M., & Mateos, D. B. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.07.009 · Cited by 13
Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective
Straka, R. J., Mamdani, M., Damen, J., Kuntze, C. E. E., Liu, L. Z., Botteman, M. F., & Koren, M. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x199808 · Cited by 13
Association between reduced left ventricular ejection fraction following non-ST-segment elevation myocardial infarction and long-term mortality in patients of advanced age
Siddiqui, A. J., & Holzmann, M. J. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.019 · Cited by 13
The Transforming Growth Factor-β/Smad3 Pathway
Seo, D., & Hare, J. M. (2007) · Circulation · doi:10.1161/circulationaha.107.735381 · Cited by 13
Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis
Mahajan, K., Nagendra, L., Dhall, A., & Dutta, D. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.02.004 · Cited by 14
Effect of rosuvastatin on risk markers for venous thromboembolism in cancer
Ades, S., Douce, D., Holmes, C. E., Cory, S., Prior, S. M., Butenas, S., CALLAS, P. W., & Cushman, M. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14004 · Cited by 12
Achieving lipid targets within 12 months of an acute coronary syndrome: an observational analysis
Alsadat, N., Hyun, K. K., Boroumand, F., Juergens, C., Kritharides, L., & Brieger, D. B. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51442 · Cited by 12
Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study
Zhao, S., Peng, D., Yu, B., & Huo, Y. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.030 · Cited by 12
Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial
Fujisue, K., Yamanaga, K., Nagamatsu, S., Shimomura, H., Yamashita, T., Nakao, K., Nakamura, S., Ishihara, M., Matsui, K., Sakaino, N., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.54726 · Cited by 12
Mortality and predictors of survival in patients with recent ventricular septal rupture
Kageyama, S., Nakanishi, Y., Murata, K., Nawada, R., Onodera, T., Sakamoto, A., Yamazaki, F., Miura, Y., & Maekawa, Y. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01652-7 · Cited by 12
Anti-Inflammatory Strategies for Plaque Stabilization after Acute Coronary Syndromes
Baruch, A., van Bruggen, N., Kim, J. B., & Lehrer‐Graiwer, J. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0327-7 · Cited by 12
The emerging role of lipidomics
Stock, J. K. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.030 · Cited by 11
High HDL cholesterol level after treatment with pitavastatin is an important factor for regression in carotid intima–media thickness
on behalf of the Samurai Study Investigators, Okumura, K., Tsukamoto, H., Tsuboi, H., Hirayama, H., Kamiya, H., Watarai, M., Ishiki, R., & Murohara, T. (2014) · Heart and Vessels · doi:10.1007/s00380-013-0466-3 · Cited by 11
Cardiovascular Disease
Braun, L. T. (2006) · The Journal of Cardiovascular Nursing · doi:10.1097/00005082-200611001-00004 · Cited by 11
2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document
Volpe, M., Volpe, R., Gallo, G., Presta, V., Tocci, G., Folco, E., Peracino, A. P., Tremoli, E., & Trimarco, B. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0211-6 · Cited by 11
Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial
Raposeiras‐Roubín, S., Assi, E. A., Jiménez-Méndez, C., de la Guía, E. M., Pérez-Rivera, J.-Á., Mangas, M. M., Ayesta, A., Uribarri, A., Jorge‐Pérez, P., Muiños, P. J. A., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.075388 · Cited by 10
Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review
Chen, C., Wei, F., Dong, Y., & Liu, C. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07587-9 · Cited by 10
Changes in coronary plaque morphology in patients with acute coronary syndrome versus stable angina pectoris after initiation of statin therapy
Gin, A. L., Vergallo, R., Minami, Y., Ong, D., Hou, J., Jia, H., Soeda, T., Hu, S., Zhang, S., Lee, H., et al. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000415 · Cited by 10
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(09)72176-2 · Cited by 10
Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable and acute coronary heart disease in the United Arab Emirates
Almahmeed, W. A., Bakir, S., Beshyah, S., Morcos, B., Wajih, S., Horack, M., Lautsch, D., Ambegaonkar, B. M., Brudi, P., Baxter, C. A., et al. (2019) · Heart Views · doi:10.4103/heartviews.heartviews_32_18 · Cited by 10
Current Statin Usage for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Multicenter Survey in Korea
Kim, M., Jeon, D. S., Gwon, H., Kim, S. J., Chang, K., Kim, H.-S., Tahk, S., & for Korean MUSTANG Investigators (2012) · Clinical Cardiology · doi:10.1002/clc.22038 · Cited by 10
Clinical Equivalence of Proprietary and Generic Atorvastatin in Lipid Clinic Patients
Rahalkar, A. R., Ban, M. R., & Hegele, R. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.05.010 · Cited by 10
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Bejarano, J. M. L., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2009) · Atención Primaria · doi:10.1016/j.aprim.2008.10.024 · Cited by 11
Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: The FAST-MI registries
Desjobert, E., Tea, V., Schiele, F., Ferrières, J., Simon, T., Danchin, N., & Puymirat, É. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.06.003 · Cited by 10
Triglycerides and cardiovascular risk
Jones, A. F. (2012) · Heart · doi:10.1136/heartjnl-2012-302968 · Cited by 10
Prescribing Statins to Reduce Cardiovascular Disease: 10 Common Misconceptions
Schade, D. S., Shey, L., & Eaton, R. P. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.042 · Cited by 10
End‐stage renal disease patients using angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study
Lee, H., See, L., Chan, Y., Yeh, Y., Wu, L., Liu, J., Tu, H., Wang, C., Kuo, C.-T., & Chang, S. (2018) · Internal Medicine Journal · doi:10.1111/imj.13971 · Cited by 9
Has cost inhibited the uptake of more potent statins in England?
Chapman, S., Fitzpatrick, R. W., & Aladul, M. I. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4231 · Cited by 9
Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention
Guedeney, P., Baber, U., Claessen, B. E. P. M., Aquino, M. B., Camaj, A., Sorrentino, S., Vogel, B., Farhan, S., Faggioni, M., Chandrasekhar, J., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.001 · Cited by 9
Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes
Ray, K. K., & Cannon, C. P. (2007) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-007-0050-1 · Cited by 9
Self-citation

Authors: Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
Monash University (AU)
Harvard University (US)
Guy's Hospital (GB)
Corresponding author: Cannon, Christopher P.
ORCID: Ray, Kausik K.
Cannon, Christopher P.
Tonkin, Andrew M.
Sacks, Frank M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-10
Volume: 46
Issue: 8
Pages: 1405-1410
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2005.03.077
OpenAlex: W1484156179
Cited by: 356
References: 9
Citations by year: 2026: 10 · 2025: 13 · 2024: 5 · 2023: 12 · 2022: 13 · 2021: 4 · 2020: 15 · 2019: 11 · 2018: 17 · 2017: 15 · 2016: 14 · 2015: 11 · 2014: 18 · 2013: 20 · 2012: 24
FWCI: 26.64
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2845 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords: atorvastatin, acute coronary syndrome, high-intensity statin therapy, pravastatin, PROVE IT-TIMI 22, pleiotropy, myocardial infarction, hospital readmission, long-term clinical outcomes
MeSH terms: Atorvastatin, Acute Disease, Angina, Unstable, Double-Blind Method, Female, Heptanoic Acids, Humans, Male, Middle Aged, Myocardial Infarction, Pyrroles, Syndrome, Time Factors, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks